

A Review on Helicobacter Pylori Infection

Prashi P. Bajpai¹, Rashmi Sonkusare², Pranit Chouvan³, Sakshi Bawankule, Sayali Ghyar

B. Pharm, New Montfort Institute of Pharmacy, Ashti, Maharashtra, India¹

M. Pharm, Asst. Prof. New Montfort Institute of Pharmacy, Ashti, Maharashtra, India²

B. Pharm, New Montfort Institute of Pharmacy, Ashti, Maharashtra, India³

Abstract: *Helicobacter pylori* continues to be a major health problem worldwide, causing considerable morbidity and mortality due to peptic ulcer disease and gastric cancer.

The burden of disease falls disproportionately on less well-resourced populations. As with most infectious diseases, the greatest impact on reducing this burden comes from improvements in socioeconomic status, which interrupt transmission. This has been observed in many regions of the world, but the prevalence of infection remains high in many regions in which improvements in living standards are slow to occur.

Meanwhile, the optimal clinical management and treatment pathways remain unsettled and are evolving with changing antimicrobial resistance patterns. Despite decades of research and clinical practice, major challenges remain. The quest for the most effective, safe, and simple therapy is still a major issue for clinicians. An effective vaccine also still appears to be elusive.

Keywords: H. Pylori, gastritis, peptic ulcer, GERD

REFERENCES

- [1]. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and *Helicobacter pylori*. *Nature*. 2007;7130:915. [PMC free article] [PubMed] [Google Scholar]
- [2]. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *The Lancet*. 1983;8336:1273–1275. [PubMed] [Google Scholar]
- [3]. Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *The Lancet*. 1984;8390:1311–1315. [PubMed] [Google Scholar]
- [4]. Peterson WL. *Helicobacter pylori* and peptic ulcer disease. *N Engl J Med*. 1991;15:1043–1048. [PubMed] [Google Scholar]
- [5]. Blaser MJ, Berg DE. *Helicobacter pylori* genetic diversity and risk of human disease. *The Journal of Clinical Investigation*. 2001;7:767–773. [PMC free article] [PubMed] [Google Scholar]
- [6]. Iwańczak B, Buchner AM, Iwańczak F. Clinical differences of *Helicobacter pylori* infection in children. *Advances in clinical and experimental medicine: official organ of Wrocław Medical University*. 2017;7:1131–1136. [PubMed] [Google Scholar]
- [7]. Salih KM, Elfaki OA, Hamid YH, et al. Prevalence of *Helicobacter Pylori* among Sudanese children admitted to a specialized children hospital. *Sudanese Journal of Paediatrics*. 2017;1:14. [PMC free article] [PubMed] [Google Scholar]
- [8]. Brown LM. *Helicobacter pylori*: epidemiology and routes of transmission. *Epidemiologic Reviews*. 2000;2:283–297. [PubMed] [Google Scholar]
- [9]. Moriai T, Hirahara N. Clinical course of acute gastric mucosal lesions caused by acute infection with *Helicobacter pylori*. *N Engl J Med*. 1999;6:456–457. [PubMed] [Google Scholar]
- [10]. Schwarz S, Morelli G, Kusecek B, Manica A, Balloux F, Owen R.J, Graham D.Y, van der M.S, Achtman M, Suerbaum S. Horizontal versus familial transmission of H. Pylori. *PLoS Pathogens*. 2008;4:e1000180. [PMC free article] [PubMed] [Google Scholar]
- [11]. Burgers R, Schneider-Brachert W, Reischl U, Behr A, Hiller KA, Lehn N, Schmalz G, Ruhl S. H. Pylori in human oral cavity and stomach. *Eur. J. Oral. Sci*. 2008;116:297–304. [PubMed] [Google Scholar]
- [12]. Gebara EC, Faria CM, Pannuti C, Chehter L, Mayer MP, Lima LA. Persistence of H. Pylori in the oral cavity after systemic eradication therapy. *I Clin.Periodont*. 2006;33:329–333. [PubMed] [Google Scholar]

- [13]. Gisbert JP, Arata IG, Boixeda D, Barba M, Canton R, Plaza AG, Pajares JM. Role of partner's infection in reinfection after H. Pylori eradication. *Gastroenterol. Hepatol.* 2002;14:865–871. [PubMed] [Google Scholar]